Xtandi is approved for men with either metastatic or non-metastatic castration-resistant prostate cancer

[Darryl]

The U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application for XTANDI (enzalutamide), based on results from the Phase 3 PROSPER trial. The FDA ruling expands XTANDI use in men with metastatic castration-resistant prostate cancer (CRPC), in addition for men with non-metastatic castration-resistant prostate cancer. XTANDI is now the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC. Very cool news to discuss with your doctor.

[JamesAtlanta]

Thanks for sharing, Darryl! Good news!

James

[PLASTICMAN]

Took Xtandi for four months. Four capsules a day. Didn't work very well. PSa went up from 2+ to 7.05 in a month. Now on docetaxel - 4 sessions already -, Eligard, and Prednisone. feel very tired and lethargic